Everolimus plus R-CHOP-21 is Safe and Highly Effective for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Phase I Trial NCCTG N1085 (Alliance)
   Google Scholar   
Citation:
Blood vol 126 (23) abstr 813
Meeting Instance:
ASH 2015
Year:
2015
Type:
Abstract
Sub type:
Oral
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Parents:
None
Children:
2456  
Program:
OGC
Primary Committee:
Lymphoma
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, UG1CA189823, U10CA180882  
Corr. Author:
 
Authors:
                     
Networks:
ADM403, ALLIANCE, LAPS-MN026   
Study
N1085
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
1
Keywords:
non-Hodgkin lymphoma, mTORC1 inhibitor, everolimus